I Manzanedo1,2, F Pereira3,4, Á Serrano3,4, E Pérez-Viejo3,4, B Martínez-Torres5, L Carrión5, J Calzas6. 1. Peritoneal Carcinomatosis Unit, Department of General and Digestive Surgery, University Hospital of Fuenlabrada, C/ Camino del Molino 2, 28942, Fuenlabrada, Madrid, Spain. israel.manzanedo@salud.madrid.org. 2. Rey Juan Carlos University (URJC), Madrid, Spain. israel.manzanedo@salud.madrid.org. 3. Peritoneal Carcinomatosis Unit, Department of General and Digestive Surgery, University Hospital of Fuenlabrada, C/ Camino del Molino 2, 28942, Fuenlabrada, Madrid, Spain. 4. Rey Juan Carlos University (URJC), Madrid, Spain. 5. Department of General and Digestive Surgery, University Hospital of Fuenlabrada, C/Camino del Molino 2, 28942, Fuenlabrada, Madrid, Spain. 6. Department of Medical Oncology, University Hospital of Fuenlabrada, C/Camino del Molino 2, 28942, Fuenlabrada, Madrid, Spain.
Abstract
PURPOSE: Our main aim is to analyze the survival results in women operated on for advanced ovarian cancer with two different HIPEC regimens (cisplatin plus doxorubicin versus paclitaxel). PATIENTS AND METHODS: A prospective cohort of patients with stage IIIC or IV epithelial ovarian cancer operated on with cytoreductive surgery and HIPEC, from October-2008 to February-2016, was retrospectively analyzed. The two drugs used, cisplatin/doxorubicin (Group A) and paclitaxel (Group B), were compared. RESULTS: Forty-one patients were treated with cytoreductive surgery and HIPEC; 19 patients (46%) were in Group A and 22 (54%) were in Group B. The extent of peritoneal disease was comparable between groups (Peritoneal Cancer Index of 10 in Group A versus PCI of 12.5 in Group B). There were no differences in morbidity between groups, with a severe morbidity (Dindo-Clavien III or IV) of 36.8% versus 27.3%, respectively. There was no postoperative mortality. Median follow-up was 39 months. Median overall survival was 79 months. Overall survival at 3 years in Group A was 66% versus 82.9% in Group B (p = 0.248). Incomplete cytoreduction (macroscopic residual tumour after surgery) was identified as the only independent factor that influenced overall survival (HR 12.30, 95% CI 1.28-118.33, p = 0.03). The cytostatic used in HIPEC had no influence in overall survival. CONCLUSION: The cytostatic used in HIPEC did not have a negative effect in the prognosis of patients with advanced ovarian cancer.
PURPOSE: Our main aim is to analyze the survival results in women operated on for advanced ovarian cancer with two different HIPEC regimens (cisplatin plus doxorubicin versus paclitaxel). PATIENTS AND METHODS: A prospective cohort of patients with stage IIIC or IV epithelial ovarian cancer operated on with cytoreductive surgery and HIPEC, from October-2008 to February-2016, was retrospectively analyzed. The two drugs used, cisplatin/doxorubicin (Group A) and paclitaxel (Group B), were compared. RESULTS: Forty-one patients were treated with cytoreductive surgery and HIPEC; 19 patients (46%) were in Group A and 22 (54%) were in Group B. The extent of peritoneal disease was comparable between groups (Peritoneal Cancer Index of 10 in Group A versus PCI of 12.5 in Group B). There were no differences in morbidity between groups, with a severe morbidity (Dindo-Clavien III or IV) of 36.8% versus 27.3%, respectively. There was no postoperative mortality. Median follow-up was 39 months. Median overall survival was 79 months. Overall survival at 3 years in Group A was 66% versus 82.9% in Group B (p = 0.248). Incomplete cytoreduction (macroscopic residual tumour after surgery) was identified as the only independent factor that influenced overall survival (HR 12.30, 95% CI 1.28-118.33, p = 0.03). The cytostatic used in HIPEC had no influence in overall survival. CONCLUSION: The cytostatic used in HIPEC did not have a negative effect in the prognosis of patients with advanced ovarian cancer.
Authors: M Markman; B N Bundy; D S Alberts; J M Fowler; D L Clark-Pearson; L F Carson; S Wadler; J Sickel Journal: J Clin Oncol Date: 2001-02-15 Impact factor: 44.544
Authors: Pedro Antonio Cascales-Campos; J Gil; E Gil; E Feliciangeli; A González-Gil; J J Parrilla; P Parrilla Journal: Ann Surg Oncol Date: 2014-03-06 Impact factor: 5.344
Authors: Francisco C Muñoz-Casares; Sebastián Rufián; María J Rubio; Carlos J Díaz; Rafael Díaz; Angela Casado; Alvaro Arjona; María C Muñoz-Villanueva; Jordi Muntané Journal: Clin Transl Oncol Date: 2009-11 Impact factor: 3.405
Authors: Willemien J van Driel; Simone N Koole; Karolina Sikorska; Jules H Schagen van Leeuwen; Henk W R Schreuder; Ralph H M Hermans; Ignace H J T de Hingh; Jacobus van der Velden; Henriëtte J Arts; Leon F A G Massuger; Arend G J Aalbers; Victor J Verwaal; Jacobien M Kieffer; Koen K Van de Vijver; Harm van Tinteren; Neil K Aaronson; Gabe S Sonke Journal: N Engl J Med Date: 2018-01-18 Impact factor: 91.245